Table 1: Fos immunoreactivity in the females.
The table only shows the regions with negative results. Animals were subjected to adolescent CVS (adol) and concomitantly administered CORT108297 (30mg/Kg) or vehicle for 2 weeks starting at PND 46. Brains were collected 2h after the onset of FST, after 6 weeks of recovery from adol CVS. Data are presented as mean ± s.e.m (n number).
| Female Fos Immunoreactivity | ||||
|---|---|---|---|---|
| Brain region (Fos-ir positive nuclei/area) | Control-Vehicle | Control-C108297 | CVS-Vehicle | CVS-C108297 |
| PL (Fos-ir/mm2) | 133.32 ± 15.12 (8) | 166.62 ± 30.25 (8) | 122.78 ± 12.87 (8) | 140.88 ± 26.61 (8) |
| IL (Fos-ir/0.1 mm2) | 13.77 ± 1.8 (8) | 14.41 ± 2.11 (8) | 12.473 ± 1.54 (8) | 14.17 ± 2.4 (8) |
| PVN (Fos-ir/0.01 mm2) | 45.96 ± 8.80 (6) | 43.20 ± 11.72 (6) | 28.14 + 7.73 (7) | 33.16 ± 8.62 (7) |
| MeAm (Fos-ir/0.1 mm2) | 17.01 ± 2.11 (7) | 16.92 ± 2.98 (7) | 13.8 ± 1.50 (8) | 17.90 ± 2.16 (8) |
| CeAm (Fos-ir/0.1 mm2) | 5.072 ± 1.09 (7) | 5.98 ± 1.42 (7) | 4.466 ± 0.81 (8) | 4.49 ± 0.83 (7) |
| BLA (Fos-ir/0.1 mm2) | 4.38 ± 0.82 (7) | 6.59 ± 1.30 (7) | 4.939 ± 0.58 (8) | 5.50 ± 0.66 (8) |
| PVA (Fos-ir/0.01 mm2) | 28.77 ± 5.99 (7) | 26.29 ± 6.21 (7) | 27.89 ± 3.72 (5) | 38.85 ± 11.37 (6) |
| PV (Fos-ir/0.01 mm2) | 34.56 ± 3.08 (5) | 27.67 ± 5.69 (7) | 24.37 ± 3.69 (5) | 36.15 ± 6.58 (6) |
| PVP (Fos-ir/0.01 mm2) | 30.41 ± 3.72 (6) | 23.05 ± 5.15 (7) | 32.18 ± 5.30 (5) | 27.89 ± 6.43 (7) |